Yes, Pluvicto Treats Prostate Cancer
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is an FDA-approved radioligand therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). It targets PSMA on cancer cells, delivering radiation to shrink tumors and extend survival. The FDA granted approval in March 2022 based on the VISION trial, which showed a 38% reduction in risk of death versus standard care alone [1][2].
How Pluvicto Works in Prostate Cancer
Pluvicto binds to PSMA proteins overexpressed on prostate cancer cells. The attached lutetium-177 isotope emits beta radiation, damaging DNA in targeted cells while sparing most healthy tissue. Patients receive it via IV infusion every 6 weeks for up to 6 cycles, after androgen receptor pathway inhibition and taxane-based chemotherapy. PSMA-PET imaging confirms eligibility [1][3].
Who Qualifies for Pluvicto Treatment
Treatment targets men with:
- PSMA-positive mCRPC confirmed by imaging.
- Disease progression on prior therapies like AR inhibitors (e.g., enzalutamide) and chemotherapy.
- No active unmanaged symptoms from bone metastases.
It's not for earlier-stage prostate cancer or PSMA-negative tumors. Novartis manufactures and markets it [1][2].
Common Side Effects and Patient Experiences
Fatigue, dry mouth, nausea, anemia, and kidney issues top the list, with 10-20% of patients needing dose reductions. Long-term risks include salivary gland damage causing dry mouth in ~40% of cases. Patients report improved quality of life in trials, with median overall survival of 15.3 months versus 11.3 months on standard care [1][3].
Pluvicto versus Other Prostate Cancer Options
| Therapy | Key Use | Survival Benefit (VISION-like trials) | Common Drawbacks |
|---------|---------|--------------------------------------|------------------|
| Pluvicto | PSMA+ mCRPC post-chemo | +4 months median OS | Kidney/salivary toxicity |
| Xtandi (enzalutamide) | Earlier mCRPC/HSPC | +4-5 months in some settings | Fatigue, seizures |
| Keytruda (pembrolizumab) | MSI-high tumors only | Variable, immunotherapy | Immune-related events |
| Xofigo (radium-223) | Bone-dominant mCRPC | +3.6 months OS | Anemia, fractures |
Pluvicto excels in PSMA+ cases but requires specialized centers for handling radioactive doses [2][4].
Ongoing Trials and Future Access
Phase 3 trials like PSMAfore (pre-chemo mCRPC) and PSMAddition (with androgen deprivation) test earlier use. Novartis seeks label expansions. Generic or biosimilar entry awaits patent expiry around 2035-2040 [5].
Patent Status and Exclusivity Timeline
Pluvicto holds U.S. patents until at least 2037 for the lutetium-PSMA conjugate, with pediatric exclusivity to 2038. No major challenges filed yet. Check DrugPatentWatch.com for updates on litigation or Paragraph IV filings [5].
Sources
[1]: FDA Approval Label
[2]: Novartis Pluvicto Page
[3]: VISION Trial NEJM
[4]: ASCO Comparison Data
[5]: DrugPatentWatch.com - Pluvicto